Feasibility study of FOLFIRINOX as first-line chemotherapy for metastatic pancreatic cancer (KOBE FOLFIRINOX study)

被引：0
|
作者：
Hatachi, Yukimasa [1 ]
Satake, Hironaga [1 ]
Kotake, Takeshi [1 ]
Ogata, Takatsugu [1 ]
Okita, Yoshihiro [2 ]
Yasui, Hisateru [1 ]
Tsuji, Akihito [2 ]
机构：
[1] Kobe City Med Ctr Gen Hosp, Dept Med Oncol, Kobe, Hyogo, Japan
[2] Kagawa Univ Hosp, Dept Clin Oncol, Miki, Kagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-104
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer
    Xu, Xifeng
    Wu, Qiong
    Wang, Zhen
    Zheng, Song
    Ge, Ke
    Jia, Changku
    CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 19 (01) : 149 - 157
  • [22] Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer
    Xifeng Xu
    Qiong Wu
    Zhen Wang
    Song Zheng
    Ke Ge
    Changku Jia
    Clinical and Experimental Medicine, 2019, 19 : 149 - 157
  • [23] CHEMOTHERAPY Metastatic pancreatic cancer-is FOLFIRINOX the new standard?
    Saif, M. Wasif
    Chabot, John
    NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (08) : 452 - 453
  • [24] A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer
    Ulusakarya, Ayhan
    Karaboue, Abdoulaye
    Ciacio, Oriana
    Pittau, Gabriella
    Haydar, Mazen
    Biondani, Pamela
    Gumus, Yusuf
    Chebib, Amale
    Almohamad, Wathek
    Innominato, Pasquale F.
    BMC CANCER, 2020, 20 (01)
  • [25] A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer
    Ayhan Ulusakarya
    Abdoulaye Karaboué
    Oriana Ciacio
    Gabriella Pittau
    Mazen Haydar
    Pamela Biondani
    Yusuf Gumus
    Amale Chebib
    Wathek Almohamad
    Pasquale F. Innominato
    BMC Cancer, 20
  • [26] Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric A.
    Aran, Dvir
    JAMA NETWORK OPEN, 2022, 5 (06) : E2216199
  • [27] Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapy.
    Cartwright, Thomas H.
    Ginsburg, Aimee
    Wilfong, Lalan S.
    Harrell, Robyn K.
    Hoverman, J. Russell
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] Redefining the use of a first-line FOLFIRINOX-like regimen in older patients with metastatic pancreatic cancer.
    Winer, Arthur
    Ioffe, Dina
    Ruth, Karen J.
    Ross, Eric A.
    Bynum, Katrina
    Mikkelsen, Eli
    Astsaturov, Igor A.
    Cann, Christopher G.
    Vijayvergia, Namrata
    Wookey, Vanessa
    Cannon, Timothy Lewis
    Wadlow, Raymond Couric
    Huynh, Jasmine
    Lee, Yoomi
    Dotan, Efrat
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 681 - 681
  • [29] Impact of Sarcopenia on Survival in Patients Treated with FOLFIRINOX in a First-Line Setting for Metastatic Pancreatic Carcinoma
    Lellouche, Lisa
    Barat, Maxime
    Pellat, Anna
    Leroux, Juliette
    Corre, Felix
    Hallit, Rachel
    Assaf, Antoine
    Brezault, Catherine
    Dhooge, Marion
    Soyer, Philippe
    Coriat, Romain
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (06)
  • [30] Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
    Okusaka, Takuji
    Ikeda, Masafumi
    Fukutomi, Akira
    Ioka, Tatsuya
    Furuse, Junji
    Ohkawa, Shinichi
    Isayama, Hiroyuki
    Boku, Narikazu
    CANCER SCIENCE, 2014, 105 (10) : 1321 - 1326
12345